株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アブレーション装置:医療機器のパイプライン評価

Ablation Equipments - Medical Devices Pipeline Assessment, 2017

発行 GlobalData 商品コード 346490
出版日 ページ情報 英文 145 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.28円で換算しております。
Back to Top
アブレーション装置:医療機器のパイプライン評価 Ablation Equipments - Medical Devices Pipeline Assessment, 2017
出版日: 2018年01月01日 ページ情報: 英文 145 Pages
概要

当レポートでは、アブレーション装置のパイプライン製品の各開発段階における比較分析などの詳細情報やパイプライン製品の開発に携わっている主な企業 (組織) の概要、現在治験が進行中のパイプライン製品の情報などを提供しています。

第1章 目次

第2章 イントロダクション

  • アブレーション装置の概要

第3章 開発中の製品

  • アブレーション装置 - 開発段階別のパイプライン製品
  • アブレーション装置 - 国 (地域) 別のパイプライン製品
  • アブレーション装置 - 規制別のパイプライン製品
  • アブレーション装置 - 認証時期別 (推定) のパイプライン製品
  • アブレーション装置 - 現在進行中の治験

第4章 アブレーション装置 - 開発中のパイプライン製品:企業別

  • アブレーション装置企業 - 開発段階別のパイプライン製品
  • アブレーション装置 - 開発段階別のパイプライン製品

第5章 アブレーション装置企業と製品の概要

  • AngioDynamics, Inc.の企業概要
    • AngioDynamics, Inc. - パイプライン製品と現在進行中の治験の概要
  • AtriCure, Inc.の企業概要
    • AtriCure, Inc. - パイプライン製品と現在進行中の治験の概要
  • CPSI Biotechの企業概要
    • CPSI Biotech - パイプライン製品と現在進行中の治験の概要
  • EP Global Communications, Inc.の企業概要
    • EP Global Communications, Inc. - パイプライン製品と現在進行中の治験の概要
  • HistoSonics, Inc.の企業概要
    • HistoSonics, Inc. - パイプライン製品と現在進行中の治験の概要
  • Hospital for Special Surgeryの企業概要
    • Hospital for Special Surgery - パイプライン製品と現在進行中の治験の概要
  • Innoblative Designs, Inc.の企業概要
    • Innoblative Designs, Inc. - パイプライン製品と現在進行中の治験の概要
  • Integra LifeSciences Holdings Corporationの企業概要
    • Integra LifeSciences Holdings Corporation - パイプライン製品と現在進行中の治験の概要
  • Intratherm, Llcの企業概要
    • Intratherm, Llc - パイプライン製品と現在進行中の治験の概要
  • Medtronic plcの企業概要
    • Medtronic plc - パイプライン製品と現在進行中の治験の概要
  • Mirabilis Medica, Inc.の企業概要
    • Mirabilis Medica, Inc. - パイプライン製品と現在進行中の治験の概要
  • Northwestern Universityの企業概要
    • Northwestern University - パイプライン製品と現在進行中の治験の概要
  • Prosurg, Inc.の企業概要
    • Prosurg, Inc. - パイプライン製品と現在進行中の治験の概要
  • Sanarus Technologies, LLCの企業概要
    • Sanarus Technologies, LLC - パイプライン製品と現在進行中の治験の概要
  • Smith & Nephew Plcの企業概要
    • Smith & Nephew Plc - パイプライン製品と現在進行中の治験の概要
  • Thermedical, Inc.の企業概要
    • Thermedical, Inc. - パイプライン製品と現在進行中の治験の概要
  • TransEnterix, Inc.の企業概要
    • TransEnterix, Inc. - パイプライン製品と現在進行中の治験の概要
  • University of California, San Franciscoの企業概要
    • University of California, San Francisco - パイプライン製品と現在進行中の治験の概要
  • University of Texas at Austinの企業概要
    • University of Texas at Austin - パイプライン製品と現在進行中の治験の概要
  • University of Wisconsin-Stoutの企業概要
    • University of Wisconsin-Stout - パイプライン製品と現在進行中の治験の概要

第6章 アブレーション装置 - 最近の動向

第7章 付録

目次
Product Code: GDME0501EPD

GlobalData's Medical Devices sector report, "Ablation Equipments - Medical Devices Pipeline Assessment, 2017" provides an overview of Ablation Equipments currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ablation Equipments pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Ablation Equipments under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Ablation Equipments and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Ablation Equipments under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Introduction 8

  • 2.1 Ablation Equipments Overview 8

3 Products under Development 9

  • 3.1 Ablation Equipments - Pipeline Products by Stage of Development 9
  • 3.2 Ablation Equipments - Pipeline Products by Territory 10
  • 3.3 Ablation Equipments - Pipeline Products by Regulatory Path 11
  • 3.4 Ablation Equipments - Pipeline Products by Estimated Approval Date 12
  • 3.5 Ablation Equipments - Ongoing Clinical Trials 13

4 Ablation Equipments - Pipeline Products under Development by Companies 14

  • 4.1 Ablation Equipments Companies - Pipeline Products by Stage of Development 14
  • 4.2 Ablation Equipments - Pipeline Products by Stage of Development 15

5 Ablation Equipments Companies and Product Overview 16

  • 5.1 AngioDynamics Inc Company Overview 16
    • 5.1.1 AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.2 CPSI Biotech Company Overview 28
    • 5.2.1 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.3 Creo Medical Ltd. Company Overview 30
    • 5.3.1 Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.4 Harmonic Medical Inc Company Overview 32
    • 5.4.1 Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.5 HistoSonics Inc Company Overview 35
    • 5.5.1 HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.6 Hospital for Special Surgery Company Overview 38
    • 5.6.1 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.7 Imricor Medical Systems Inc Company Overview 39
    • 5.7.1 Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.8 Innoblative Designs, Inc. Company Overview 42
    • 5.8.1 Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.9 Integra LifeSciences Holdings Corp Company Overview 43
    • 5.9.1 Integra LifeSciences Holdings Corp Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.10 Intratherm, Llc Company Overview 44
    • 5.10.1 Intratherm, Llc Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.11 Medtronic plc Company Overview 45
    • 5.11.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.12 Memorial Sloan Kettering Cancer Center Company Overview 47
    • 5.12.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.13 Mirabilis Medical Inc Company Overview 48
    • 5.13.1 Mirabilis Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.14 Prosurg Inc Company Overview 51
    • 5.14.1 Prosurg Inc Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.15 Pulse Biosciences, Inc. Company Overview 52
    • 5.15.1 Pulse Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.16 Southern Illinois University Carbondale Company Overview 57
    • 5.16.1 Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.17 Thermedical Inc Company Overview 58
    • 5.17.1 Thermedical Inc Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.18 TransEnterix, Inc. Company Overview 59
    • 5.18.1 TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.19 University of California San Francisco Company Overview 60
    • 5.19.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.20 University of Texas at Austin Company Overview 61
    • 5.20.1 University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.21 University of Wisconsin-Stout Company Overview 62
    • 5.21.1 University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview 62

6 Ablation Equipments- Recent Developments 63

  • 6.1 Dec 12, 2017: Stryker announces Mr. Howard E. Cox, Jr. will retire from Board of Directors 63
  • 6.2 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results 63
  • 6.3 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue 66
  • 6.4 Nov 07, 2017: Misonix Reports First Quarter Fiscal Year 2018 Financial Results 67
  • 6.5 Nov 06, 2017: Ethicon Celebrates 130 Years of Transforming Surgery to Advance Patient Outcomes 68
  • 6.6 Nov 03, 2017: Smith & Nephew Third Quarter 2017 Trading Report 68
  • 6.7 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report 69
  • 6.8 Nov 01, 2017: AtriCure Reports Third Quarter 2017 Financial Results 70
  • 6.9 Oct 26, 2017: Stryker reports third quarter 2017 results 70
  • 6.10 Oct 26, 2017: Integra LifeSciences Reports Third Quarter 2017 Financial Results 72
  • 6.11 Oct 25, 2017: Baylis Medical's Kris Shah appointed to AdvaMed Accel Board of Directors 73
  • 6.12 Oct 19, 2017: CLS signs supplier agreement with University of Texas Medical Branch and receives the first order 73
  • 6.13 Oct 18, 2017: Relievant Medsystems Names Ray M. Baker, M.D. as Chief Medical Officer 74
  • 6.14 Oct 09, 2017: Smith & Nephew: Notice of Chief Executive Officer's intention to retire by end of 2018 74
  • 6.15 Oct 09, 2017: Notice of Chief Executive Officer's intention to retire by end of 2018 75
  • 6.16 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 75
  • 6.17 Oct 02, 2017: Smith & Nephew Announces Directorate Change 77
  • 6.18 Sep 28, 2017: AngioDynamics Reports Fiscal 2018 First Quarter Results 77
  • 6.19 Sep 26, 2017: Integra LifeSciences Provides Preliminary Assessment of Minor Damage to its Manufacturing Facility in Anasco, Puerto Rico 78
  • 6.20 Sep 20, 2017: SonaCare Medical Reports that CMS Announces Increase to ASC Payment for HIFU Prostate Ablation 78
  • 6.21 Sep 19, 2017: Relievant Medsystems Names Kevin Hykes Chief Executive Officer 79
  • 6.22 Sep 19, 2017: HistoSonics Expands Leadership Team As It Accelerates Growth 79
  • 6.23 Sep 18, 2017: Smith & Nephew Announces Change in Board of Directors 81
  • 6.24 Sep 12, 2017: Smith & Nephew: Appointment of Marc Owen as Non-Executive Director 81
  • 6.25 Sep 11, 2017: Pulse Biosciences Announces Withdrawal and Planned Resubmission of 510(k) Application for the PulseTx System 81
  • 6.26 Aug 23, 2017: Misonix Appoints Joseph Dwyer as Chief Financial Officer 82
  • 6.27 Aug 23, 2017: Baylis Medical strengthens global expansion plans with senior hire 82
  • 6.28 Aug 22, 2017: Misonix Reports Fiscal Year 2017 Financial Results 83
  • 6.29 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 84
  • 6.30 Aug 09, 2017: Novadaq Receives Court Approval for Arrangement With Stryker 87
  • 6.31 Aug 02, 2017: Stryker announces election of new Director, Mary K. Brainerd 87
  • 6.32 Jul 27, 2017: Smith & Nephew Second Quarter and First Half 2017 Results 87
  • 6.33 Jul 27, 2017: Stryker reports second quarter 2017 results 91
  • 6.34 Jul 27, 2017: AtriCure Reports Second Quarter 2017 Financial Results 92
  • 6.35 Jul 26, 2017: Integra LifeSciences Reports Second Quarter 2017 Financial Results 92
  • 6.36 Jul 18, 2017: AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results 94
  • 6.37 Jul 18, 2017: AtriCure Announces Hiring of Chief Technology Officer 96
  • 6.38 Jul 04, 2017: Appointment of Angie Risley as Non-Executive Director and Chairman Elect of the Remuneration Committee 96
  • 6.39 Jun 29, 2017: FDA Confirms 510(K) Submission Pathway For Creo's Flexible Ablation System 97
  • 6.40 Jun 19, 2017: CSA Medical Appoints Jean Bjerke, Vice President of Marketing 97
  • 6.41 Jun 07, 2017: AngioDynamics Announces FDA Clearance for The Solero Microwave Tissue Ablation System 98
  • 6.42 Jun 07, 2017: HistoSonics Announces Addition to Management Team 98
  • 6.43 Jun 06, 2017: Pulse Biosciences Announces Treatment of First Patient in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation Technology for Seborrheic Keratosis Lesions 99
  • 6.44 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 99
  • 6.45 May 17, 2017: Syneron Medical Reports First Quarter 2017 Revenue of $66.9 Million 102
  • 6.46 May 12, 2017: Smith & Nephew opens state-of-the-art Research & Development Centre 104
  • 6.47 May 10, 2017: The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures 104
  • 6.48 May 05, 2017: Smith & Nephew 2017 First Quarter Trading Report 105
  • 6.49 May 04, 2017: AtriCure Reports First Quarter 2017 Financial Results 107
  • 6.50 May 04, 2017: Olympus Extends Portfolio of EndoTherapy Solutions at DDW 108
  • 6.51 May 02, 2017: Misonix Reports Third Quarter Fiscal Year 2017 Financial Results 109
  • 6.52 Apr 26, 2017: Integra LifeSciences Reports First Quarter 2017 Financial Results 109
  • 6.53 Apr 25, 2017: Stryker reports first quarter 2017 results 111
  • 6.54 Apr 20, 2017: Key Appointment to Board of Directors at Cianna Medical 112
  • 6.55 Mar 30, 2017: AngioDynamics Reports Fiscal 2017 Third Quarter Results 113
  • 6.56 Mar 23, 2017: Mirabilis Medical Announces European Approval for Non-Invasive Uterine Fibroid Treatment 114
  • 6.57 Mar 23, 2017: Mirabilis receives FDA approval for US clinical study 115
  • 6.58 Mar 14, 2017: Pulse Biosciences Submits 510(k) Application to FDA for PulseTx System 115
  • 6.59 Mar 14, 2017: AngioDynamics Receives CE Mark Certification for The Solero Microwave Tissue Ablation System 115
  • 6.60 Mar 13, 2017: Misonix Announces Second Quarters of Fiscal 2017 116
  • 6.61 Mar 13, 2017: HistoSonics Appoints Mike Blue as CEO and Board Member 117
  • 6.62 Mar 13, 2017: Misonix Files Forms 10-Q for First and Second Quarters of Fiscal 2017 117
  • 6.63 Mar 06, 2017: AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs 119
  • 6.64 Mar 06, 2017: TransEnterix Reports Operating Results for the Fourth Quarter and Full Year 2016 119
  • 6.65 Feb 28, 2017: AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results 120
  • 6.66 Feb 23, 2017: Integra LifeSciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Updates 2017 Full-Year Guidance 121
  • 6.67 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 123
  • 6.68 Feb 15, 2017: Syneron Medical Reports Fourth Quarter 2016 Revenue of $82.9 Million and Full Year 2016 Revenue $298.1 Million 126
  • 6.69 Feb 09, 2017: Smith & Nephew Fourth Quarter Trading and Full Year 2016 Results 127
  • 6.70 Feb 09, 2017: Smith & Nephew: Directorate Change 132
  • 6.71 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 132
  • 6.72 Jan 31, 2017: Syneron Medical Strengthens Senior Management Team with Appointment of Chief Human Resources Officer 133
  • 6.73 Jan 24, 2017: Stryker reports 2016 results and 2017 outlook 134
  • 6.74 Jan 17, 2017: Aurora Cancer Care is first in Wisconsin to perform new Nanoknife therapy technique to treat pancreatic and liver cancers 135
  • 6.75 Jan 12, 2017: Confirmation of CFO leaving Smith & Nephew 136
  • 6.76 Jan 10, 2017: Stryker provides 2016 preliminary net sales results 136
  • 6.77 Jan 09, 2017: AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016 138
  • 6.78 Jan 06, 2017: AngioDynamics Reports Fiscal 2017 Second Quarter Results 139
  • 6.79 Dec 19, 2016: Stavros G. Vizirgianakis Appointed President and CEO of Misonix 140

7 Appendix 142

  • 7.1 Methodology 142
  • 7.2 About GlobalData 145
  • 7.3 Contact Us 145
  • 7.4 Disclaimer 145

List of Tables

1.1 List of Tables

  • Table 1: Ablation Equipments - Pipeline Products by Stage of Development 9
  • Table 2: Ablation Equipments - Pipeline Products by Territory 10
  • Table 3: Ablation Equipments - Pipeline Products by Regulatory Path 11
  • Table 4: Ablation Equipments - Pipeline Products by Estimated Approval Date 12
  • Table 5: Ablation Equipments - Ongoing Clinical Trials 13
  • Table 6: Ablation Equipments Companies - Pipeline Products by Stage of Development 14
  • Table 7: Ablation Equipments - Pipeline Products by Stage of Development 15
  • Table 8: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 16
  • Table 9: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status 16
  • Table 10: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description 17
  • Table 11: NanoKnife System - Pancreatic Cancer - Product Status 17
  • Table 12: NanoKnife System - Pancreatic Cancer - Product Description 17
  • Table 13: NanoKnife System - Prostate Cancer - Product Status 18
  • Table 14: NanoKnife System - Prostate Cancer - Product Description 18
  • Table 15: Next Generation NanoKnife System - Product Status 18
  • Table 16: Next Generation NanoKnife System - Product Description 19
  • Table 17: AngioDynamics Inc - Ongoing Clinical Trials Overview 20
  • Table 18: NanoKnife System - Prostate Cancer - Irreversible Electroporation(IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial 21
  • Table 19: NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer 21
  • Table 20: NanoKnife System - Pancreatic Cancer - A Clinical Research about Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer 22
  • Table 21: NanoKnife System - Pancreatic Cancer - A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas 22
  • Table 22: NanoKnife System - Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study 22
  • Table 23: NanoKnife System - Pancreatic Cancer - IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer 23
  • Table 24: NanoKnife System - Pancreatic Cancer - Pilot-study: Non-thermal Ablation Using Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma - A Phase I Clinical Trial - PANFIRE 23
  • Table 25: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder 24
  • Table 26: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers 24
  • Table 27: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial (COLDFIRE-2 Study) 24
  • Table 28: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer 25
  • Table 29: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome 25
  • Table 30: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE) 25
  • Table 31: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial 26
  • Table 32: Next Generation NanoKnife System - The Safety and Feasibility of Irreversible Electroporation for the Ablation of Small Renal Masses 27
  • Table 33: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 34: Pressurized Sub-Cooled Nitrogen System - Product Status 28
  • Table 35: Pressurized Sub-Cooled Nitrogen System - Product Description 28
  • Table 36: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Status 29
  • Table 37: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Description 29
  • Table 38: Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 39: Flexible Ablation System - Product Status 30
  • Table 40: Flexible Ablation System - Product Description 30
  • Table 41: Lung Ablation Device - Product Status 31
  • Table 42: Lung Ablation Device - Product Description 31
  • Table 43: Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 44: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Status 32
  • Table 45: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Description 32
  • Table 46: Harmonic Medical Inc - Ongoing Clinical Trials Overview 33
  • Table 47: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - MRI-guided High Intensity Focused Ultrasound Ablation of Leiomyomas. Single Arm, Feasibility Study Using the Symphony - MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas. 34
  • Table 48: HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 49: Vortx RX - Product Status 35
  • Table 50: Vortx RX - Product Description 35
  • Table 51: HistoSonics Inc - Ongoing Clinical Trials Overview 36
  • Table 52: Vortx RX - Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US) 37
  • Table 53: Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 54: Radiofrequency Ablation Device - Product Status 38
  • Table 55: Radiofrequency Ablation Device - Product Description 38
  • Table 56: Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 57: Vision MR Ablation Catheter - Product Status 39
  • Table 58: Vision MR Ablation Catheter - Product Description 39
  • Table 59: Imricor Medical Systems Inc - Ongoing Clinical Trials Overview 40
  • Table 60: Vision MR Ablation Catheter - Cardiovascular Magnetic Resonance-guided Radiofrequency-Ablation for Atrial Flutter 41
  • Table 61: Vision MR Ablation Catheter - Evaluation of MR-enabled Systems in the Treatment of Atrial Flutter: A Prospective Pilot Study 41
  • Table 62: Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 63: RFA Applicator - Product Status 42
  • Table 64: RFA Applicator - Product Description 42
  • Table 65: Integra LifeSciences Holdings Corp Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 66: CUSA Ultrasonic Tissue Ablation System - Liver - Product Status 43
  • Table 67: CUSA Ultrasonic Tissue Ablation System - Liver - Product Description 43
  • Table 68: Intratherm, Llc Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 69: CITT Device - Product Status 44
  • Table 70: CITT Device - Product Description 44
  • Table 71: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 72: Barrx 360 Express RFA Balloon Catheter - Product Status 45
  • Table 73: Barrx 360 Express RFA Balloon Catheter - Product Description 45
  • Table 74: Nerve Cryoablation System - Product Status 46
  • Table 75: Nerve Cryoablation System - Product Description 46
  • Table 76: Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 77: Image-Guided Ablation Device - Product Status 47
  • Table 78: Image-Guided Ablation Device - Product Description 47
  • Table 79: Mirabilis Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 80: Mirabilis System - Product Status 48
  • Table 81: Mirabilis System - Product Description 48
  • Table 82: Mirabilis Medical Inc - Ongoing Clinical Trials Overview 49
  • Table 83: Mirabilis System - Directed Ablation of Uterine Fibroids Using a Noninvasive Approach: DIANA 50
  • Table 84: Prosurg Inc Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 85: ImaGel - Product Status 51
  • Table 86: ImaGel - Product Description 51
  • Table 87: Pulse Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 88: PulseTx System - Seborrheic Keratosis - Product Status 52
  • Table 89: PulseTx System - Seborrheic Keratosis - Product Description 52
  • Table 90: PulseTx System - Soft Tissue Ablation - Product Status 53
  • Table 91: PulseTx System - Soft Tissue Ablation - Product Description 53
  • Table 92: Pulse Biosciences, Inc. - Ongoing Clinical Trials Overview 54
  • Table 93: PulseTx System - Soft Tissue Ablation - First-of-its-kind PulseTx System in Pilot Study in Dermatology 55
  • Table 94: PulseTx System - Seborrheic Keratosis - Clinical Evaluation of Safety and Efficacy of Nano-pulse Stimulation Technology for Seborrheic Keratosis Lesions 56
  • Table 95: Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 96: Thermoablation Probe - Product Status 57
  • Table 97: Thermoablation Probe - Product Description 57
  • Table 98: Thermedical Inc Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 99: SERF Ablation System - Fibroids - Product Status 58
  • Table 100: SERF Ablation System - Fibroids - Product Description 58
  • Table 101: TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 102: Barrett's Excision Device - Product Status 59
  • Table 103: Barrett's Excision Device - Product Description 59
  • Table 104: University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 105: Robotic Needle Ablation Tool And Securement Device - Product Status 60
  • Table 106: Robotic Needle Ablation Tool And Securement Device - Product Description 60
  • Table 107: University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 108: Plasmonic Laser Ablation Device - Product Status 61
  • Table 109: Plasmonic Laser Ablation Device - Product Description 61
  • Table 110: University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 111: Microwave Ablation Probe - Product Status 62
  • Table 112: Microwave Ablation Probe - Product Description 62
  • Table 113: Glossary 144

List of Figures

1.2 List of Figures

  • Figure 1: Ablation Equipments - Pipeline Products by Stage of Development 9
  • Figure 2: Ablation Equipments - Pipeline Products by Territory 10
  • Figure 3: Ablation Equipments - Pipeline Products by Regulatory Path 11
  • Figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date 12
  • Figure 5: Ablation Equipments - Ongoing Clinical Trials 13
Back to Top